NEW YORK, Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ: TLX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.  

The investigation concerns whether Telix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

NEW YORK, July 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ: TLX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.  

The investigation concerns whether Telix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

MELBOURNE, Australia and INDIANAPOLIS, July 30, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August 2025.

An investor webcast and conference call will be held at 9.30am AEST on Thursday 21 August 2025 (7.30pm EDT Wednesday 20 August 2025).   

NEW YORK, July 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ: TLX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.  

The investigation concerns whether Telix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated otherwise.

Q2 2025 Highlights 

MELBOURNE, Australien, 20. Juli 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, „Telix") gibt heute bekannt, dass sein Prostatakrebs-PET[1] -Bildgebungsmittel Illuccix® (Kit zur Herstellung einer Gallium-68-Gozetotid-Injektion) vom BASG[2] die Zulassung für den Nachweis und die Lokalisierung von Prostata-spezifischen Membran-Antigen (PSMA)-positiven Läsionen bei Erwachsenen mit Prostatakrebs erhalten hat, eine breite klinische Bezeichnung. Diese Zulassung ermöglicht es Gesundheitsdienstleistern in Österreich, PSMA-PET[3] Bildgebung unter Verwendung eines klinisch validierten Radiopharmakons auf Galliumbasis anzubieten.

MELBOURNE, Australia, July 9, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that its next-generation PSMA[1] PET[2] imaging agent, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), has been granted a permanent Healthcare Common Procedure Coding System (HCPCS) code by the U.S. Centers for Medicare & Medicaid Services (CMS).

MELBOURNE, Australia and INDIANAPOLIS, June 25, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that its Telix Manufacturing Solutions (TMS) facility in Brussels South (Seneffe), Belgium, has produced its first Good Manufacturing Practice (GMP)-grade commercial radiopharmaceutical doses and delivered them to the AIRC [1] hospital collaboration in Charleroi, Belgium.

TMS Brussels South is one of Europe's largest radiopharmaceutical production facilities, with nine GMP lines, clean rooms, a radiopharmacy, and two cyclotrons across a 2,800 square metre footprint.

MELBOURNE, Australia, June 13, 2025 /PRNewswire/ --Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by the Greek EOF[2] for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer - a broad clinical label. This approval enhances the options available to healthcare providers across Greece for PSMA-PET[3] imaging using a clinically-validated, gallium-based radiopharmaceutical. 

MELBOURNE, Australien, 11. Juni 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, „Telix", „Unternehmen") gibt heute bekannt, dass sein bildgebendes Mittel Illuccix® (Kit zur Herstellung einer Gallium-68-Gozetotid-Injektion) für Prostatakrebs-PET[1] in Deutschland vom BfArM[2] die Zulassung für den Nachweis und die Lokalisierung von Prostata-spezifischen Membranantigen-(PSMA-)positiven Läsionen bei Erwachsenen mit Prostatakrebs erhalten hat – eine breite klinische Indikation. Diese Zulassung erweitert die Möglichkeiten, die Gesundheitsdienstleistern in Deutschland für die Bildgebung via PSMA-PET[3] zur Verfügung stehen, und stellt sicher, dass mehr Patienten Zugang zu diesem wichtigen diagnostischen Instrument erhalten.